|
5.5.1 ASCO (général)
|
|
|
|
5.5.1.1 ASCO (général) - Industriels
|
|
|
|
|
Winners And Losers From Cancer Research's Biggest Event [Forbes]
|
|
|
|
|
|
What's
also striking is that this non-industry study of a generic drug was
more cautious and rigorous than a lot of the single-arm studies being
used by biotechnology companies. Whether metformin works or not, that's a
warning to industry to dot i's and cross t's.
|
|
|
|
|
|
|
5.5.10 ASCO (hémato)
|
|
|
|
5.5.13 ASCO (divers)
|
|
|
|
|
|
|
5.5.16 ASCO (médecine de précision)
|
|
|
|
5.5.16.2 ASCO (médecine de précision-sein)
|
|
|
|
Breast cancer test 'reduces need for chemotherapy' [NHS Choices]
|
|
|
|
|
|
Contrary
to some of the media stories, this study, though important, will not
necessarily lead to instant changes in the treatment people are
receiving in the UK. NICE is in the process of updating guidance on the
use of this test, and will likely consider this study alongside other
evidence in forming recommendations.
|
|
|
|
|
|
|
|
|
5.5.17 ASCO (pancréas)
|
|
|
|
|
Chemotherapy Regimen Extends Life by Nearly Twenty Months for People With Pancreatic Cancer [ASCO]
|
|
|
|
|
|
“For
the first time, our trial shows a large benefit from adjuvant
FOLFIRINOX chemotherapy over standard chemotherapy with gemcitabine,
showing we can help patients with pancreatic cancer live much longer,”
said lead study author Thierry Conroy, MD, a medical oncologist and
director of the Institut de Cancerologie de Lorraine in Nancy, one of
the UNICANCER comprehensive cancer centers in France.
|
|
|
|
|
|
|
|
|
5.5.2 ASCO (sein)
|
|
|
|
|
|
5.5.3 ASCO (prostate)
|
|
|
|
5.5.4.4 ASCO (immunothérapies-poumon)
|
|
|
|
|
|
|
|
|
5.5.4.5 ASCO (immunothérapies-CAR-T, thérapies cellulaires)
|
|
|
|
|
|
|
|
5.5.4.6 ASCO (immunothérapies-mélanome)
|
|
|
|
|
|
5.5.5 ASCO (gastro-intestinal)
|
|
|
|
5.5.8 ASCO (poumon)
|
|
|
|
5.5.9 ASCO (autres organes)
|
|
|